Bayer's Organic Chemicals Business Group is aiming to become more active in the market for fine chemicals, which is currently valued at some $30 billion a year.
Fine chemicals are the basis for high-quality end-products such as pharmaceuticals, crop protection agents, veterinary products, dyestuffs, pigments, cosmetics and fragrances, flavors and aroma chemicals.
The company says its options are being expanded through the construction of a new multi-purpose plant and the modification of existing plants, and the acquisition of ChemDesign Corp has broadened the Group's production options in the USA. Accompanying its broad range and considerable know-how over fine chemicals, the Group is increasingly offering intermediates tailored specifically to customers' needs, ie custom manufacturing.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze